Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	SHANK1 NFKBIZ IRF4 PNKP MRTFB SH2D3C	1.26e-03	1160	22	6	GO:0030674
GeneOntologyMolecularFunction	signaling receptor complex adaptor activity	SHANK1 SH2D3C	1.60e-03	54	22	2	GO:0030159
GeneOntologyMolecularFunction	nuclear receptor activity	ESR2 NR1I2	1.97e-03	60	22	2	GO:0004879
GeneOntologyMolecularFunction	ligand-activated transcription factor activity	ESR2 NR1I2	2.04e-03	61	22	2	GO:0098531
GeneOntologyMolecularFunction	molecular adaptor activity	SHANK1 NFKBIZ IRF4 PNKP MRTFB SH2D3C	2.81e-03	1356	22	6	GO:0060090
GeneOntologyMolecularFunction	scaffold protein binding	SHANK1 ITPR2	4.67e-03	93	22	2	GO:0097110
Domain	VitD_rcpt	ESR2 NR1I2	1.20e-04	14	22	2	IPR000324
Domain	zf-C4	ESR2 NR1I2	1.33e-03	46	22	2	PF00105
Domain	NUCLEAR_REC_DBD_1	ESR2 NR1I2	1.33e-03	46	22	2	PS00031
Domain	Znf_hrmn_rcpt	ESR2 NR1I2	1.33e-03	46	22	2	IPR001628
Domain	Nuclear_hrmn_rcpt	ESR2 NR1I2	1.33e-03	46	22	2	IPR001723
Domain	ZnF_C4	ESR2 NR1I2	1.33e-03	46	22	2	SM00399
Domain	NUCLEAR_REC_DBD_2	ESR2 NR1I2	1.33e-03	46	22	2	PS51030
Domain	-	ESR2 NR1I2	1.39e-03	47	22	2	1.10.565.10
Domain	Nucl_hrmn_rcpt_lig-bd	ESR2 NR1I2	1.45e-03	48	22	2	IPR000536
Domain	Hormone_recep	ESR2 NR1I2	1.45e-03	48	22	2	PF00104
Domain	HOLI	ESR2 NR1I2	1.45e-03	48	22	2	SM00430
Domain	SMAD_FHA_domain	IRF4 PNKP	1.69e-03	52	22	2	IPR008984
Domain	-	ESR2 NR1I2	2.03e-03	57	22	2	3.30.50.10
Domain	Znf_NHR/GATA	ESR2 NR1I2	2.10e-03	58	22	2	IPR013088
Domain	Ion_trans_dom	SCN2A ITPR2	7.88e-03	114	22	2	IPR005821
Domain	Ion_trans	SCN2A ITPR2	7.88e-03	114	22	2	PF00520
Domain	PDZ	SHANK1 ARHGAP23	1.18e-02	141	22	2	PF00595
Domain	PDZ	SHANK1 ARHGAP23	1.30e-02	148	22	2	SM00228
Domain	-	SHANK1 ARHGAP23	1.33e-02	150	22	2	2.30.42.10
Domain	TPR-contain_dom	ANAPC5 SMG7	1.33e-02	150	22	2	IPR013026
Domain	PDZ	SHANK1 ARHGAP23	1.35e-02	151	22	2	PS50106
Domain	PDZ	SHANK1 ARHGAP23	1.37e-02	152	22	2	IPR001478
Domain	TPR	ANAPC5 SMG7	1.60e-02	165	22	2	PS50005
Domain	TPR_REGION	ANAPC5 SMG7	1.60e-02	165	22	2	PS50293
Pubmed	Phytoestrogen exposure is associated with circulating sex hormone levels in postmenopausal women and interact with ESR1 and NR1I2 gene variants.	ESR2 NR1I2	1.15e-06	3	22	2	17507630
Pubmed	Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.	ESR2 NR1I2	3.82e-06	5	22	2	19739075
Pubmed	Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity.	ESR2 NR1I2	3.82e-06	5	22	2	16606610
Pubmed	Sex Hormones Regulate SHANK Expression.	SHANK1 ESR2	1.07e-05	8	22	2	30319350
Pubmed	Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.	ESR2 NR1I2 NUMA1	5.45e-05	117	22	3	19124506
Pubmed	An atlas of combinatorial transcriptional regulation in mouse and man.	NFKBIZ ZNF407 IRF4 ESR2 NR1I2	1.86e-04	877	22	5	20211142
Pubmed	A Dynamic Splicing Program Ensures Proper Synaptic Connections in the Developing Cerebellum.	SHANK1 NUMA1	3.56e-04	44	22	2	32492419
Interaction	NCOA3 interactions	IRF4 ESR2 MRTFB NR1I2 SMG7	3.66e-06	224	22	5	int:NCOA3
Interaction	NCOA6 interactions	ESR2 NR1I2 NUMA1 SMG7	1.70e-05	145	22	4	int:NCOA6
GeneFamily	Nuclear hormone receptors	ESR2 NR1I2	8.43e-04	49	16	2	71
GeneFamily	PDZ domain containing	SHANK1 ARHGAP23	7.80e-03	152	16	2	1220
GeneFamily	Ankyrin repeat domain containing	SHANK1 NFKBIZ	1.89e-02	242	16	2	403
ToppCell	droplet-Liver-nan-3m-Lymphocytic\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZNF407 SH2D3C ITPR2	6.96e-05	164	22	3	bf0d3ad9016a0b8011a2385bb92f0a4f5edad1d6
ToppCell	droplet-Liver-nan-3m-Lymphocytic-NK/T\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZNF407 SH2D3C ITPR2	6.96e-05	164	22	3	c33910a6d87580902e9e7bd27afe6ea63b5eff8d
ToppCell	droplet-Liver-nan-3m-Lymphocytic-NK_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZNF407 SH2D3C ITPR2	6.96e-05	164	22	3	950f87d9dacee45c9004a9bf894543de38f72ee5
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5\|TCGA-Ovary / Sample_Type by Project: Shred V9	KANSL1L NUMA1 SMG7	7.21e-05	166	22	3	32d2eaf8a5d03881bf74d680825af2d5110b082d
ToppCell	5'-GW_trimst-2-LargeIntestine-Hematopoietic-T_cells-LTi-like_NCR+_ILC3\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SHANK1 IRF4 ESR2	8.87e-05	178	22	3	0b59e3d75b143bd7bf91a7800a49699c51e68c5a
ToppCell	Control-Epithelial_cells-Airway_mucous\|Control / group, cell type (main and fine annotations)	PTPRN2 MUC3A SCN2A	9.63e-05	183	22	3	15d24a4fb1ffe6cbafbd54fcd7dde9ddcfbe03b2
ToppCell	Substantia_nigra-Neuronal\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	SHANK1 PTPRN2 SCN2A	1.01e-04	186	22	3	3f889083fcffe516388e9b03a5e23af2010ced33
ToppCell	Control-Endothelial-VE_Venous\|Endothelial / Disease state, Lineage and Cell class	NFKBIZ MRTFB ITPR2	1.08e-04	190	22	3	4e30155203b4a8c5e496fcbe9348b67b98ebc625
ToppCell	Entopeduncular-Neuronal-Inhibitory\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	PTPRN2 SCN2A SCRT1	1.09e-04	191	22	3	73dae4cdea86aec62393ad7303dc7375a6b3fc86
ToppCell	Entopeduncular-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	PTPRN2 SCN2A SCRT1	1.09e-04	191	22	3	5d24022cec293bc8d9e978ae99a109e660bb8f83
ToppCell	P15-Endothelial-large_vessel_endothelial_cell\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	NFKBIZ ESR2 MRTFB	1.13e-04	193	22	3	5f9a7cd5f8eb9ac294cdb50518fedf872f3f78f5
ToppCell	TCGA-Adrenal-Primary_Tumor-Pheochromocytoma\|TCGA-Adrenal / Sample_Type by Project: Shred V9	PTPRN2 SCN2A SCRT1	1.14e-04	194	22	3	b6488bc3a8905e926ad298332963e1bbaf010046
ToppCell	TCGA-Adrenal-Primary_Tumor-Pheochromocytoma-Pheochromocytoma\|TCGA-Adrenal / Sample_Type by Project: Shred V9	PTPRN2 SCN2A SCRT1	1.14e-04	194	22	3	1e1f4139ad584f493d75a9b7f1568eca4653c5a2
ToppCell	primary_visual_cortex-Neuronal\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SHANK1 PTPRN2 SCN2A	1.18e-04	196	22	3	8efc2b3a95f57c31be203ac781b2098d4909297f
ToppCell	frontal_cortex-Neuronal\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SHANK1 PTPRN2 SCN2A	1.18e-04	196	22	3	de7d10da862f98894ce47244fbc992f4a12d63bb
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 SCN2A MRTFB	1.18e-04	196	22	3	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 SCN2A MRTFB	1.22e-04	198	22	3	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 SCN2A MRTFB	1.22e-04	198	22	3	8ab40fae14fe02e39bc8c8da187a5cd60c787643
ToppCell	Somatosensory_Cortex_(S1)-Neuronal\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 SCN2A MRTFB	1.22e-04	198	22	3	c01091ef18e096d792ea2a7a715764a5b215355f
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRN2 SCN2A MRTFB	1.22e-04	198	22	3	4ca5ff320905ab4ff60ed90a5522227c782142a6
ToppCell	Tracheal-10x3prime_v2-Stromal-Peri/Epineurial_\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	ARHGAP23 ZNF407 NUMA1	1.25e-04	200	22	3	f7c3a8f5ac156c05ad7335d6d142c154c7d86449
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	PTPRN2 SCN2A MRTFB	1.25e-04	200	22	3	48d801219bc771d6c7e151dc88ca4c179988de85
Drug	Indoprofen [31842-01-0]; Up 200; 14.2uM; PC3; HT_HG-U133A	KANSL1L ESR2 SCN2A ITPR2 NUMA1	1.08e-06	197	22	5	4249_UP
Drug	cyanophenphos	ESR2 NR1I2	2.67e-06	3	22	2	ctd:C002488
Drug	Estradiol	ESR2 NR1I2	2.67e-06	3	22	2	DB00783
Drug	chloropropylate	ESR2 NR1I2	5.34e-06	4	22	2	ctd:C004663
Drug	ethyl bromophos	ESR2 NR1I2	5.34e-06	4	22	2	ctd:C041062
Drug	Phenylphosphonothioic Acid, 2-Ethyl 2-(4-Nitrophenyl) Ester	ESR2 NR1I2	5.34e-06	4	22	2	ctd:D004849
Drug	dichlofenthion	ESR2 NR1I2	5.34e-06	4	22	2	ctd:C011445
Drug	tolclofos-methyl	ESR2 NR1I2	8.90e-06	5	22	2	ctd:C426783
Drug	prothiophos	ESR2 NR1I2	8.90e-06	5	22	2	ctd:C032072
Drug	Leptophos	ESR2 NR1I2	8.90e-06	5	22	2	ctd:D010773
Drug	ethion	ESR2 NR1I2	8.90e-06	5	22	2	ctd:C100038
Drug	isopropyl 4,4'-dibromobenzilate	ESR2 NR1I2	1.33e-05	6	22	2	ctd:C038267
Drug	pendimethalin	ESR2 NR1I2	1.87e-05	7	22	2	ctd:C030856
Drug	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	ESR2 NR1I2	1.87e-05	7	22	2	ctd:C576261
Drug	DPMI	ESR2 NR1I2	2.49e-05	8	22	2	CID000092292
Drug	2,3,5,6-tetrafluoro-4-methylbenzyl (Z)-(1RS)-cis-3-(2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate	SCN2A NR1I2	2.49e-05	8	22	2	ctd:C489827
Drug	celestolide	ESR2 NR1I2	3.20e-05	9	22	2	CID000061585
Drug	AG-013608 [351320-38-2]; Up 200; 10uM; PC3; HT_HG-U133A	ZNF407 NR1I2 ITPR2 NUMA1	3.31e-05	194	22	4	5909_UP
Drug	Flumethasone [2135-17-3]; Down 200; 9.8uM; PC3; HT_HG-U133A	ANAPC5 ITPR2 NUMA1 SMG7	3.31e-05	194	22	4	4272_DN
Drug	Arcaine sulfate [14923-17-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	KANSL1L IRF4 NUMA1 SMG7	3.45e-05	196	22	4	4974_UP
Drug	Aminohippuric acid [61-78-9]; Down 200; 20.6uM; MCF7; HT_HG-U133A	ANAPC5 ITPR2 NUMA1 SMG7	3.45e-05	196	22	4	5394_DN
Drug	Betulinic acid [472-15-1]; Down 200; 8.8uM; PC3; HT_HG-U133A	KANSL1L ZNF407 NUMA1 SMG7	3.45e-05	196	22	4	4101_DN
Drug	CGX 0596987; Down 200; 20uM; PC3; HT_HG-U133A	KANSL1L IRF4 ITPR2 SMG7	3.52e-05	197	22	4	6369_DN
Drug	Rapamycin; Up 200; 0.1uM; HL60; HT_HG-U133A	PTPRN2 KANSL1L MRTFB NUMA1	3.52e-05	197	22	4	2667_UP
Drug	Colistin sulfate [1264-72-8]; Down 200; 3uM; HL60; HT_HG-U133A	PTPRN2 MRTFB ITPR2 NUMA1	3.52e-05	197	22	4	2491_DN
Drug	Gramine [87-52-5]; Down 200; 23uM; HL60; HT_HG-U133A	PTPRN2 KANSL1L ITPR2 SMG7	3.52e-05	197	22	4	2143_DN
Drug	fluphenazine dihydrochloride; Up 200; 10uM; HL60; HT_HG-U133A	PTPRN2 KANSL1L MRTFB ITPR2	3.59e-05	198	22	4	1178_UP
Drug	Niacin [59-67-6]; Up 200; 32.4uM; PC3; HT_HG-U133A	PTPRN2 KANSL1L ZNF407 ESR2	3.59e-05	198	22	4	6702_UP
Drug	Mycophenolic acid [24280-93-1]; Up 200; 12.4uM; PC3; HT_HG-U133A	KANSL1L ESR2 SCN2A ITPR2	3.59e-05	198	22	4	4019_UP
Drug	Procyclidine hydrochloride [1508-76-5]; Up 200; 12.4uM; PC3; HT_HG-U133A	KANSL1L ZNF407 ITPR2 NUMA1	3.59e-05	198	22	4	4233_UP
Drug	Foliosidine [2520-38-9]; Up 200; 13uM; PC3; HT_HG-U133A	PTPRN2 KANSL1L ZNF407 ESR2	3.66e-05	199	22	4	4295_UP
Drug	Karakoline [39089-30-0]; Up 200; 10.6uM; PC3; HT_HG-U133A	PTPRN2 KANSL1L IRF4 ESR2	3.66e-05	199	22	4	4297_UP
Drug	Corticosterone [50-22-6]; Down 200; 11.6uM; PC3; HT_HG-U133A	KANSL1L ZNF407 ITPR2 NUMA1	3.66e-05	199	22	4	4064_DN
Drug	Boldine [476-70-0]; Up 200; 12.2uM; HL60; HT_HG-U133A	SHANK1 PTPRN2 MRTFB NUMA1	3.73e-05	200	22	4	2148_UP
Drug	Ginkgolide A [15291-75-5]; Up 200; 9.8uM; PC3; HT_HG-U133A	ZNF407 NR1I2 ITPR2 SMG7	3.73e-05	200	22	4	4002_UP
Drug	mono-benzyl phthalate	ESR2 NR1I2	3.99e-05	10	22	2	ctd:C103325
Drug	bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate	ESR2 NR1I2	4.88e-05	11	22	2	ctd:C576262
Drug	O-desmethylangolensin	ESR2 NR1I2	5.85e-05	12	22	2	CID000089472
Drug	pentabrominated diphenyl ether 100	ESR2 NR1I2	5.85e-05	12	22	2	ctd:C517827
Drug	quinalphos	ESR2 NR1I2	5.85e-05	12	22	2	ctd:C009145
Drug	hexabrominated diphenyl ether 153	ESR2 NR1I2	6.91e-05	13	22	2	ctd:C517828
Drug	tetrachlorodian	ESR2 NR1I2	8.05e-05	14	22	2	ctd:C041181
Drug	2-phenylphenol	ESR2 NR1I2	9.29e-05	15	22	2	ctd:C004369
Drug	fenvalerate	ESR2 SCN2A NR1I2	1.09e-04	97	22	3	ctd:C017690
Drug	Dicofol	ESR2 NR1I2	1.20e-04	17	22	2	ctd:D004010
Drug	phthalic acid	ESR2 NR1I2	1.20e-04	17	22	2	ctd:C032279
Drug	Methiocarb	ESR2 NR1I2	1.35e-04	18	22	2	ctd:D008714
Drug	Methoxychlor	SHANK1 PTPRN2 ESR2 SCN2A NR1I2	1.50e-04	549	22	5	ctd:D008731
Drug	enterodiol	ESR2 NR1I2	1.51e-04	19	22	2	CID000115089
Drug	tetramethrin	ESR2 NR1I2	1.51e-04	19	22	2	ctd:C009424
Drug	methylparaben	ESR2 SCN2A	1.68e-04	20	22	2	CID000007456
Drug	delta-hexachlorocyclohexane	ESR2 NR1I2	1.68e-04	20	22	2	ctd:C086916
Drug	benzophenone	ESR2 NR1I2	1.85e-04	21	22	2	ctd:C047723
Drug	ethylparaben	ESR2 SCN2A	1.85e-04	21	22	2	CID000008434
Drug	enterolactone	ESR2 NR1I2	2.03e-04	22	22	2	CID000114739
Drug	2,2',4,4',5-brominated diphenyl ether	ESR2 NR1I2	2.86e-04	26	22	2	ctd:C477694
Drug	CsCl	PTPRN2 MUC3A PNKP	2.95e-04	136	22	3	CID000024293
Drug	cyfluthrin	SCN2A NR1I2	3.56e-04	29	22	2	ctd:C052570
Drug	Dichlorodiphenyldichloroethane	ESR2 NR1I2	3.56e-04	29	22	2	ctd:D003632
Drug	AHTN	ESR2 NR1I2	3.56e-04	29	22	2	CID000089440
Drug	fludioxonil	ESR2 NR1I2	3.81e-04	30	22	2	ctd:C108339
Drug	A19457	ESR2 NR1I2 NUMA1	3.86e-04	149	22	3	CID000004042
Drug	schizandrin	ESR2 NR1I2	4.34e-04	32	22	2	CID000023915
Drug	N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide	ESR2 NR1I2	4.34e-04	32	22	2	ctd:C451426
Drug	Endrin	ESR2 NR1I2	4.34e-04	32	22	2	ctd:D004732
Drug	fenbuconazole	ESR2 NR1I2	4.34e-04	32	22	2	ctd:C504383
Drug	SureCN1562346	ESR2 NR1I2	4.62e-04	33	22	2	CID011646228
Drug	diisobutyl phthalate	ESR2 NR1I2	4.62e-04	33	22	2	ctd:C025605
Drug	1-naphthol	ESR2 NR1I2	4.62e-04	33	22	2	ctd:C029350
Drug	nonachlor	ESR2 NR1I2	4.62e-04	33	22	2	ctd:C001870
Drug	squalestatin	SCN2A NR1I2	4.91e-04	34	22	2	CID006438355
Drug	Metyrapone	ESR2 NR1I2	4.91e-04	34	22	2	ctd:D008797
Drug	4-(3,6-dimethylheptan-3-yl)phenol	ESR2 NR1I2	4.91e-04	34	22	2	CID010633340
Drug	ON 01910	IRF4 ESR2 NUMA1	4.93e-04	162	22	3	ctd:C507134
Drug	2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene	ESR2 NR1I2	5.50e-04	36	22	2	ctd:C054919
Drug	Diosgenin	ESR2 NR1I2	5.50e-04	36	22	2	ctd:D004144
Drug	glycitein	ESR2 NR1I2	5.50e-04	36	22	2	CID005317750
Drug	N-acetylmethionine	SCN2A NUMA1	6.46e-04	39	22	2	CID000006180
Drug	4-octylphenol	ESR2 NR1I2	7.14e-04	41	22	2	ctd:C080417
Drug	LY 294002; Up 200; 10uM; PC3; HT_HG-U133A	IRF4 NUMA1 SMG7	7.37e-04	186	22	3	4460_UP
Drug	Niflumic acid [4394-00-7]; Up 200; 14.2uM; MCF7; HT_HG-U133A	KANSL1L ZNF407 SMG7	7.60e-04	188	22	3	5490_UP
Drug	CP-690334-01 [459212-38-5]; Up 200; 10uM; PC3; HT_HG-U133A	IRF4 ITPR2 SMG7	7.60e-04	188	22	3	3823_UP
Drug	Ketanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; PC3; HT_HG-U133A	PTPRN2 NUMA1 SMG7	7.72e-04	189	22	3	6649_DN
Drug	Cloperastine hydrochloride [14984-68-0]; Down 200; 11uM; PC3; HT_HG-U133A	ANAPC5 NUMA1 SMG7	7.72e-04	189	22	3	4271_DN
Drug	Securinine [5610-40-2]; Up 200; 18.4uM; HL60; HT_HG-U133A	KANSL1L ZNF407 IRF4	7.72e-04	189	22	3	2729_UP
Drug	AC1NRBRB	PTPRN2 IRF4	7.86e-04	43	22	2	CID005288597
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A	MRTFB ITPR2 NUMA1	7.96e-04	191	22	3	2137_UP
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A	KANSL1L ITPR2 NUMA1	7.96e-04	191	22	3	5200_DN
Drug	Butylparaben [94-26-8]; Down 200; 20.6uM; PC3; HT_HG-U133A	ANAPC5 NUMA1 SMG7	7.96e-04	191	22	3	4647_DN
Drug	Diphenhydramine hydrochloride [147-24-0]; Down 200; 13.8uM; MCF7; HT_HG-U133A	KANSL1L NUMA1 SMG7	7.96e-04	191	22	3	6020_DN
Drug	Phenacetin [62-44-2]; Down 200; 22.4uM; HL60; HT_HG-U133A	PTPRN2 ANAPC5 NUMA1	8.08e-04	192	22	3	2471_DN
Drug	Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; PC3; HT_HG-U133A	ANAPC5 NUMA1 SMG7	8.08e-04	192	22	3	4268_DN
Drug	Deptropine citrate [2169-75-7]; Up 200; 7.6uM; PC3; HT_HG-U133A	PTPRN2 KANSL1L IRF4	8.08e-04	192	22	3	5118_UP
Drug	Pseudopelletierine hydrochloride [6164-62-1]; Down 200; 21uM; MCF7; HT_HG-U133A	ANAPC5 ITPR2 NUMA1	8.08e-04	192	22	3	2766_DN
Drug	0175029-0000 [211245-78-2]; Up 200; 10uM; PC3; HT_HG-U133A	ANAPC5 ZNF407 ITPR2	8.08e-04	192	22	3	6875_UP
Drug	Galanthamine hydrobromide [1953-04-4]; Up 200; 10.8uM; HL60; HT_HG-U133A	NR1I2 ITPR2 NUMA1	8.20e-04	193	22	3	2131_UP
Drug	Hycanthone [3105-97-3]; Down 200; 11.2uM; PC3; HT_HG-U133A	PTPRN2 ITPR2 NUMA1	8.20e-04	193	22	3	4630_DN
Drug	Butylparaben [94-26-8]; Down 200; 20.6uM; MCF7; HT_HG-U133A	ITPR2 NUMA1 SMG7	8.20e-04	193	22	3	5608_DN
Drug	fenarimol	ESR2 NR1I2	8.23e-04	44	22	2	ctd:C033789
Drug	Fludrocortisone acetate [514-36-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A	KANSL1L ZNF407 IRF4	8.32e-04	194	22	3	3977_DN
Disease	Early infantile epileptic encephalopathy with suppression bursts	PNKP SCN2A	5.75e-05	16	21	2	C0393706
Disease	anxiety disorder (implicated_via_orthology)	ESR2 SCN2A	1.10e-04	22	21	2	DOID:2030 (implicated_via_orthology)
Disease	Subfertility, Female	ESR2 NR1I2	1.80e-04	28	21	2	C0341869
Disease	Sterility, Postpartum	ESR2 NR1I2	1.80e-04	28	21	2	C0038279
Disease	Female sterility	ESR2 NR1I2	1.80e-04	28	21	2	C0917730
Disease	Female infertility	ESR2 NR1I2	1.80e-04	28	21	2	C0021361
Disease	diffuse plaque measurement	PTPRN2 NFKBIZ IRF4 ITPR2	1.82e-03	758	21	4	EFO_0010699
Disease	Adenocarcinoma	ESR2 NR1I2	3.06e-03	116	21	2	C0001418
Disease	Carcinoma, Granular Cell	ESR2 NR1I2	3.06e-03	116	21	2	C0205644
Disease	Adenocarcinoma, Tubular	ESR2 NR1I2	3.06e-03	116	21	2	C0205645
Disease	Adenocarcinoma, Oxyphilic	ESR2 NR1I2	3.06e-03	116	21	2	C0205642
Disease	Carcinoma, Cribriform	ESR2 NR1I2	3.06e-03	116	21	2	C0205643
Disease	Adenocarcinoma, Basal Cell	ESR2 NR1I2	3.06e-03	116	21	2	C0205641
Disease	celiac disease	IRF4 SMG7	3.60e-03	126	21	2	EFO_0001060

Protein segments in the cluster

Peptide	Gene	Start	Entry
GSHQVPTMTLTTMME	ITPR2	2436	Q14571
SNMDISTGHMILSYM	PTPRN2	721	Q92932
MASVHESLYFNPMMT	ANAPC5	1	Q9UJX4
SSLPSTMESDKMLYM	KANSL1L	16	A0AUZ9
TMESDKMLYMESPRT	KANSL1L	21	A0AUZ9
LHSFSMMPSSACEAM	NFKBIZ	371	Q9BYH8
SAPFTEASMMMSLTK	ESR2	286	Q92731
LEDPQMSMSHPYTMT	IRF4	141	Q15306
MYLQPSSSHSMDTDK	OR5B3	256	Q8NH48
PMMTDLTSVYTVSSM	MUC3A	1591	Q02505
TTYMDTSSMMPESES	MUC3A	2826	Q02505
TEIMTMMSPSQFLSS	MRTFB	516	Q9ULH7
IFSLLPHMADMSTYM	NR1I2	236	O75469
HMPESDTLSTIMYSM	OR1C1	266	Q15619
AKMTMLLLYHSTMSS	NUMA1	96	Q14980
YVSMPAMAMHLLTHD	SCRT1	231	Q9BWW7
MESLKSIWSSSMMHP	SMG7	1096	Q92540
ASSSRMDLPSLEHMM	SPATA32	251	Q96LK8
MTDSSHIPVSDMVMY	PNKP	466	Q96T60
SMSVPDDAHFSMMVF	SHANK1	61	Q9Y566
RTSEDNMTDMVTHMP	ARHGAP23	1066	Q9P227
MAMEHYPMTEQFSSV	SCN2A	776	Q99250
SDMYSHMGTMPRPSI	SH2D3C	71	Q8N5H7
EEMMSLTMSSNYGSP	ZNF407	1181	Q9C0G0